Life Biosciences has initiated the first human trial of partial cellular reprogramming using three Yamanaka factors (OSK) delivered to the eye. The trial targets glaucoma and NAION (sudden vision loss). Phase I will assess safety; efficacy will be explored in later phases. This is a landmark event for epigenetic age reversal.
The TAME (Targeting Aging with Metformin) trial is the first large‑scale, placebo‑controlled study of a drug specifically for healthy aging in non‑diabetic older adults. Results are expected in 2028–2030. The trial design has become a template for future aging intervention studies.
Multiple clinical trials of the senolytic fisetin are underway: STOP‑Sepsis (multicenter), NCT06342791 (multimorbidity), and TROPHY (breast cancer survivors). No results are yet published, but the diversity of populations being studied reflects growing interest in senolytics.
A Phase II trial in China is testing dasatinib, quercetin, and an immunotherapy drug in head and neck cancer patients. This represents one of the first cancer‑focused senolytic trials outside of the US.